의약품 중간체 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the pharmaceutical intermediates market size was valued at USD 45.45 billion in 2025 and estimated to grow from USD 48.65 billion in 2026 to reach USD 68.37 billion by 2031, at a CAGR of 7.05% during the forecast period (2026-2031).

This report is Segmented by Product Type (Bulk Drug Intermediates, Custom & Contract Intermediates, and More), Therapeutic Application (Oncology, and More), Synthesis Process (Traditional Batch Chemistry, and More), End User (Generic Drug Manufacturers, and More), and Geography (North America, Europe and More ). The Market Forecasts are Provided in Terms of Value (USD), Based On Availability.

Global Pharmaceutical Intermediates Market Trends and Insights

Accelerating Shift Toward Outsourced Manufacturing

Contract services have become the production backbone for new chemical entities as drug originators prioritize capital-light models that de-risk supply chains. Full-service CDMOs now advertise 25% cost reductions and 50% timeline compression compared with in-house development. Post-pandemic boardrooms are also localizing critical intermediates; 81% of executives surveyed in 2025 planned to relocate at least one manufacturing step to a CDMO in the same economic bloc. Regulatory endorsements, notably the FDA Advanced Manufacturing Technologies Designation Program, further tilt the calculus in favor of outsourcing because certified sites gain quicker pre-approval inspection slots and shorter review cycles.

Rising Demand for Small-Molecule Oncology APIs

Twenty-five novel oncology active substances launched globally in 2024, lifting the five-year debut count to 132 and triggering a surge in specialized intermediate orders. The productivity of oncology pipelines has improved 51% since 2019, yet the underlying chemistry has grown more complex, often requiring multi-step high-potency handling and customized chiral catalysts. North American innovator companies dominate precision medicine trials, but Chinese CDMOs have gained share in second-generation tyrosine kinase inhibitors, complicating global sourcing patterns and magnifying the need for dual geography supply strategies.

Accelerating Shift Toward Outsourced Manufacturing

Contract services have become the production backbone for new chemical entities as drug originators prioritize capital-light models that de-risk supply chains. Full-service CDMOs now advertise 25% cost reductions and 50% timeline compression compared with in-house development. Post-pandemic boardrooms are also localizing critical intermediates; 81% of executives surveyed in 2025 planned to relocate at least one manufacturing step to a CDMO in the same economic bloc. Regulatory endorsements, notably the FDA Advanced Manufacturing Technologies Designation Program, further tilt the calculus in favor of outsourcing because certified sites gain quicker pre-approval inspection slots and shorter review cycles.

Other drivers and restraints analyzed in the detailed report include:

1. Re-shoring Incentives in the United States & Europe
2. Growing Investments in Continuous-Flow Chemistry
3. Rising Demand for Small-Molecule Oncology APIs

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Bulk drug intermediates retained leadership with 48.10% of pharmaceutical intermediates market share in 2025, anchored by high-volume small-molecule generics and mature therapies. Peptide & oligonucleotide intermediates, though smaller in absolute value, are forecast to outpace at an 7.85% CAGR as biologic-like chemical entities gain clinical momentum. Custom & contract intermediates continue to flourish because innovators prefer turnkey synthesis that meets accelerated filing timelines.

The pharmaceutical intermediates market size for chiral & high-potency intermediates is expanding steadily on the back of oncology pipelines that demand precise stereochemistry and specialized containment. CDMOs able to combine flow chemistry with advanced hazardous-material management are winning multi-year master service agreements, indicating a structural shift toward premium, low-volume, high-margin subsegments.

Oncology generated 37.20% of revenue in 2025 and is projected to maintain a 7.35% CAGR, reinforcing its status as the chief value driver within the pharmaceutical intermediates market. Immuno-oncology combinations and antibody-drug conjugates necessitate intricate linker chemistry, elevating demand for ultrapure intermediates. Cardiovascular agents, though moderating after several patent expiries, continue to require sizable base intermediates given the chronic-care prevalence.

Central nervous system candidates are re-emerging as AI-discovered molecules enter trials, a trend likely to accelerate specialized amide and heterocycle intermediate consumption. Infectious disease programs remain strategically important as governments stockpile antivirals and vaccines, sustaining medium-volume demand. Metabolic disorders, especially obesity, stimulate peptide intermediate orders tied to GLP-1 agonists.

Complete Report Scope:

• By Product Type
  • Bulk Drug Intermediates
  • Custom & Contract Intermediates
  • Peptide & Oligonucleotide Intermediates
  • Chiral & High-Potency Intermediates
• By Therapeutic Application
  • Oncology
  • Cardiovascular
  • Infectious Diseases
  • Central Nervous System
  • Metabolic & Others
• By Synthesis Process
  • Traditional Batch Chemistry
  • Continuous-Flow Chemistry
  • Biocatalytic & Enzymatic Routes
• By End User
  • Generic Drug Manufacturers
  • Innovative Pharma Companies
  • Contract Research & Manufacturing Organizations (CROs/CDMOs)
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

North America generated 41.80% of 2025 revenue, buoyed by USD 160 billion in announced manufacturing investments and a policy environment that rewards domestic sourcing. The FDA PreCheck program and draft shortage-mitigation plans are already shortening inspection queues, encouraging both incumbents and new entrants to qualify U.S. sites. Canada complements the regional ecosystem with regulatory modernization aimed at averting ingredient shortages, thereby cementing cross-border supply resilience.

Asia-Pacific is forecast to post the fastest 8.02% CAGR between 2026 and 2031. India's CRDMO community is scaling high-potency and antibody-drug conjugate services, while China sustains leadership in commodity APIs despite emerging compliance costs linked to revised environmental statutes. Bilateral frameworks such as the India-U.S. TRUST Initiative underscore the strategic imperative of diversified sourcing away from single-country concentration. Southeast Asian nations are also courting investment with free-trade zones and expedited clearance for greenfield facilities.

Europe remains a critical pillar, emphasizing sustainability and advanced therapy readiness. Synthetic APIs account for 77% of the region's output, yet policy makers are subsidizing relocation of select intermediates as part of supply-security drives. Continuous-manufacturing retrofits across Ireland, Belgium, and Germany signal a technological leap that could close cost gaps with low-cost jurisdictions. Moreover, updated EU GMP Annexes and the European Medicines Agency's three-year work plan reinforce consistent quality expectations, raising the entry bar for new suppliers.

1. Lonza Group
2. WuXi AppTec Co., Ltd.
3. Thermo Fisher Scientific
4. Cambrex
5. Siegfried Holding AG
6. Divi's Laboratories Ltd.
7. Aarti Industries Limited
8. Curia Global, Inc.
9. Dishman Carbogen Amcis Ltd.
10. Jubilant Pharmova Limited
11. Sanofi
12. Merck
13. BASF
14. Hetero Labs Limited
15. Pfizer
16. Asymchem Laboratories
17. Porton Pharma Solutions Ltd.
18. Almac Group Ltd.
19. Laxmi Organic Industries Ltd.
20. Esteve Quimica

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Accelerating shift toward outsourced manufacturing
  • 4.2.2 Rising demand for small-molecule oncology APIs
  • 4.2.3 Re-shoring incentives in the United States & Europe
  • 4.2.4 Growing investments in continuous-flow chemistry
  • 4.2.5 Expansion of nucleotide & oligonucleotide drug pipelines
  • 4.2.6 AI-enabled route scouting and synthesis optimization
• 4.3 Market Restraints
  • 4.3.1 Volatile prices of key raw materials (solvents, reagents)
  • 4.3.2 Stringent environmental-impact compliance costs
  • 4.3.3 Geopolitical export controls on dual-use precursors
  • 4.3.4 CDMO capacity bottlenecks for highly-potent intermediates
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD billion)

• 5.1 By Product Type
  • 5.1.1 Bulk Drug Intermediates
  • 5.1.2 Custom & Contract Intermediates
  • 5.1.3 Peptide & Oligonucleotide Intermediates
  • 5.1.4 Chiral & High-Potency Intermediates
• 5.2 By Therapeutic Application
  • 5.2.1 Oncology
  • 5.2.2 Cardiovascular
  • 5.2.3 Infectious Diseases
  • 5.2.4 Central Nervous System
  • 5.2.5 Metabolic & Others
• 5.3 By Synthesis Process
  • 5.3.1 Traditional Batch Chemistry
  • 5.3.2 Continuous-Flow Chemistry
  • 5.3.3 Biocatalytic & Enzymatic Routes
• 5.4 By End User
  • 5.4.1 Generic Drug Manufacturers
  • 5.4.2 Innovative Pharma Companies
  • 5.4.3 Contract Research & Manufacturing Organizations (CROs/CDMOs)
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 South America
    • 5.5.4.1 Brazil
    • 5.5.4.2 Argentina
    • 5.5.4.3 Rest of South America
  • 5.5.5 Middle East and Africa
    • 5.5.5.1 GCC
    • 5.5.5.2 South Africa
    • 5.5.5.3 Rest of Middle East and Africa

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global-level Overview, Market-level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 Lonza Group AG
  • 6.3.2 WuXi AppTec Co., Ltd.
  • 6.3.3 Thermo Fisher Scientific Inc.
  • 6.3.4 Cambrex Corporation
  • 6.3.5 Siegfried Holding AG
  • 6.3.6 Divi's Laboratories Ltd.
  • 6.3.7 Aarti Industries Limited
  • 6.3.8 Curia Global, Inc.
  • 6.3.9 Dishman Carbogen Amcis Ltd.
  • 6.3.10 Jubilant Pharmova Limited
  • 6.3.11 Sanofi S.A.
  • 6.3.12 Merck KGaA
  • 6.3.13 BASF SE
  • 6.3.14 Hetero Labs Limited
  • 6.3.15 Pfizer Inc.
  • 6.3.16 Asymchem Laboratories
  • 6.3.17 Porton Pharma Solutions Ltd.
  • 6.3.18 Almac Group Ltd.
  • 6.3.19 Laxmi Organic Industries Ltd.
  • 6.3.20 Esteve Quimica

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment